The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice
histologically confirmed diagnosis of adenocarcinoma of the prostate, metastatic, not undergoing previous treatment (except hormone therapy initiated no more than 4-6 months prior to docetaxel) for metastatic disease
treatment with docetaxel, ARPI (alone or in combination) or with radiation therapy on the primary tumor in combination with ADT within normal clinical practice or expanded access programs initiated between January 2015 and December 2027.
availability of inpatient and/or outpatient medical records for clinical data collection
histological diagnosis other than adenocarcinoma
patients who have received multiple lines of ADT for mCSPC
patients who have received docetaxel or ARTA for metastatic castration-resistant disease
Santa Chiara Hospital
Lead sponsor